MNPR · NASDAQ · Biotechnology

Monopar Therapeutics

Develops ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals for oncology.

$111.89
After-hours close−0.50 (−0.44%)
At close$112.39(−1.36%)
DateEstimateReportedSurprise
Nov 2026−$0.86
Aug 2026−$0.64−$0.62+3.5%
Aug 2026−$0.66−$0.62+5.4%
May 2026−$1.06−$0.46+56.6%
Mar 2026−$0.51−$0.61−19.1%

The latest year is open to everyone — the 39 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Dec 2019
Aug 2019
May 2019
Feb 2019
Nov 2018
Aug 2018
May 2018
Mar 2018
Sep 2017
Jun 2017
Mar 2017
Dec 2016
Sep 2016
Jun 2016
Mar 2016
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 12, 2026−$0.86
Aug 12, 2026−$0.64−$0.62+3.5%
Aug 11, 2026−$0.66−$0.62+5.4%
May 14, 2026−$1.06−$0.46+56.6%
Mar 27, 2026−$0.51−$0.61−19.1%

The latest year is open to everyone — the 39 quarters behind it read with an account.

Sign in
Nov 13, 2025
Aug 12, 2025
May 13, 2025
Mar 31, 2025
Nov 8, 2024
Aug 9, 2024
May 9, 2024
Mar 28, 2024
Nov 9, 2023
Aug 10, 2023
May 11, 2023
Mar 23, 2023
Nov 10, 2022
Aug 11, 2022
May 12, 2022
Mar 24, 2022
Nov 12, 2021
Aug 12, 2021
May 13, 2021
Mar 25, 2021
Nov 12, 2020
Aug 6, 2020
May 7, 2020
Mar 27, 2020
Dec 23, 2019
Aug 8, 2019
May 10, 2019
Feb 26, 2019
Nov 9, 2018
Aug 9, 2018
May 11, 2018
Mar 26, 2018
Sep 30, 2017
Jun 30, 2017
Mar 31, 2017
Dec 31, 2016
Sep 30, 2016
Jun 30, 2016
Mar 31, 2016